Stay updated on Safety of Single Dose UB-221 in Urticaria Clinical Trial
Sign up to get notified when there's something new on the Safety of Single Dose UB-221 in Urticaria Clinical Trial page.

Latest updates to the Safety of Single Dose UB-221 in Urticaria Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check27 days agoChange DetectedThe web page has added new sections on Immunologic Factors, Physiological Effects of Drugs, and Antibodies, Monoclonal, enhancing its core content significantly.SummaryDifference0.5%
- Check35 days agoChange DetectedThe page has undergone significant content changes, including the removal of detailed information about a clinical study on UB-221, which included safety and efficacy evaluations, and the addition of terms related to chronic idiopathic urticaria and immunologic factors.SummaryDifference18%
- Check42 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check71 days agoChange DetectedThe page has been updated to include new sections on Immunologic Factors, Physiological Effects of Drugs, and Antibodies, Monoclonal.SummaryDifference0.5%
- Check85 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference2%
Stay in the know with updates to Safety of Single Dose UB-221 in Urticaria Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety of Single Dose UB-221 in Urticaria Clinical Trial page.